Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Biotech reported standalone revenue from operations of Rs. 20,398.76 lakhs for Q1 FY26, down about 5.5% from Rs. 21,580.17 lakhs in Q1 FY25. Standalone profit after tax fell sharply to Rs. 4,256.55 lakhs from Rs. 5,823.86 lakhs, a decline of roughly 27% year-on-year, with EPS dropping to Rs. 4.07 from Rs. 5.57. Operating profit margins also compressed meaningfully, with PBT margin falling to about 28% from 36% a year ago, driven by higher depreciation and other expenses. The board also declared a dividend of Rs. 10.70 per share for FY25 with a record date of September 3, 2025. The statutory auditor BSR & Co. LLP issued a limited review report with an unmodified opinion.
Negative quarterly performance with both revenue and profits declining significantly, and margins contracting, which could weigh on near-term stock sentiment. The healthy dividend declaration and clean audit opinion are modest positives for shareholders.